Abstract:Abstract Background Interleukin-33 (IL-33) is an effective inducer of pro-inflammatory cytokines regulating innate and adaptive immunity. Inflammation could be a double-edged sword, promoting or inhibiting tumour growth. To date, the roles and mechanisms of IL-33 in tumours remain controversial. Here, we examined the effect of exogenous IL-33 on the biological characteristics of hepatocellular carcinoma (HCC) and the possible mechanism of action. Methods In this study, IL-33 expression in the tissues of 69 HCC patients was detected and its relationship with prognosis was evaluated. After establishing a mouse HCC model and IL-33 treatment operation, the infiltration of splenic myeloid-derived suppressor (MDSCs), dendritic (DCs), regulatory T, and natural killer (NK) cells was detected by flow cytometry analysis, and the vascular density of the tumour tissues was detected by immunohistochemistry to reveal the mechanism of IL-33 in HCC proliferation. Finally, the Cancer Genome Atlas database was used to analyse Gene Ontology terms the and Kyoto Encyclopaedia of Genes and Genomes pathway. Moreover, the chi-square test, two-tailed unpaired Student’s t -test, and multiple t- tests were performed using SPSS version 23.0 and GraphPad Prism 8.0 software. Results The IL-33 expression level was negatively correlated with the overall survival of HCC patients, suggesting its potential clinical significance in the prognosis of HCC. We found that systemic IL-33 administration significantly promoted the tumour size in vivo. Furthermore, the IL-33-treated mice presented decreased frequencies of tumouricidal NK and CD69 + CD8 + T cells. After IL-33 treatment, the incidence of monocytic MDSCs and conventional DCs increased, while that of granulocytic MDSCs decreased. Moreover, IL-33 promoted the formation of intracellular neovascularization. Therefore, IL-33 accelerated HCC progression by increasing the accumulation of immunosuppressive cells and neovascularization formation. Finally, we found that the transcription of IL-33 was closely related to the PI3K-Akt and MAPK pathways in Gene Set Enrichment Analysis plots, which were involved in the tumourigenesis and pathogenesis of HCC. Conclusions Taken together, IL-33 may be a key tumour promoter of HCC proliferation and tumourigenicity, an important mediator, and a potential therapeutic target for regulating HCC progression.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the effect of exogenous interleukin - 33 (IL - 33) on the growth of hepatocellular carcinoma (HCC) and its underlying mechanisms. Specifically, the researchers focused on the following aspects: 1. **The expression level of IL - 33 in HCC and its relationship with patient prognosis**: - The researchers detected the expression level of IL - 33 in tissue samples from 69 HCC patients and evaluated its relationship with patient prognosis. The results showed that high expression of IL - 33 was significantly associated with a shortened overall survival (OS) and disease - free survival (DFS) in HCC patients, suggesting that IL - 33 may be a marker of poor prognosis in HCC. 2. **The effect of exogenous IL - 33 on HCC mouse models**: - The researchers established a mouse model of HCC and observed the effect of IL - 33 on tumor growth by intraperitoneal injection of recombinant IL - 33 protein. The results found that IL - 33 treatment significantly promoted the growth of HCC, as manifested by an increase in tumor volume and weight. 3. **The remodeling effect of IL - 33 on the tumor microenvironment (TME)**: - The researchers analyzed the changes in immune cells in the spleen and tumor tissues of mice after IL - 33 treatment by flow cytometry. The results showed that IL - 33 increased the proportion of inhibitory immune cells (such as regulatory T cells and myeloid - derived suppressor cells) in the spleen, while reducing the proportion of cytotoxic NK cells and activated CD8+ T cells in the tumor tissue. These changes contribute to tumor immune escape and growth. 4. **IL - 33 induces the formation of pro - inflammatory factors and new blood vessels**: - The researchers detected the expression levels of pro - inflammatory factors (such as IL - 1β) and chemokines (such as Csf2, Ccl2, Ccl5, Cxcl1) in tumor tissues after IL - 33 treatment. The results showed that IL - 33 significantly up - regulated the expression of these factors, promoting the inflammatory response and the formation of new blood vessels in the tumor. 5. **Function and pathway analysis of IL - 33 - related genes**: - Through GO and KEGG pathway enrichment analysis, the researchers found that IL - 33 - related genes are mainly involved in biological processes such as extracellular matrix organization and endothelial cell migration, and are related to important pathways such as the PI3K - Akt signaling pathway, the cGMP - PKG signaling pathway, and the calcium signaling pathway, which are closely related to tumorigenesis and development. In summary, this paper aims to reveal that exogenous IL - 33 accelerates the progression of HCC through mechanisms such as remodeling the tumor microenvironment, promoting the inflammatory response and the formation of new blood vessels, and to explore its potential as a therapeutic target.

Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment

Infiltrating Regulatory T Cells Promote Invasiveness of Liver Cancer Cells Via Inducing Epithelial-Mesenchymal Transition

CHI3L1 Promotes Tumor Progression by Activating TGF-β Signaling Pathway in Hepatocellular Carcinoma.

Interleukin 35 Activates Intratumor Neovascularization Via Enhanced Secretion of FGF2 in Hepatocellular Carcinoma Through The Recruitment of Neutrophils, and Blocking it Could Facilitate The Efficacy of The PD-1 Antibody

Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy

Role of IL-33 Expression in Oncogenesis and Development of Human Hepatocellular Carcinoma.

Interleukin-2 Inducible T-cell Kinase: a Potential Prognostic Biomarker and Tumor Microenvironment Remodeling Indicator for Hepatocellular Carcinoma.

IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4+ and CD8+ T Cell Responses in Hepatocellular Carcinoma

Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Cmar_a_262745 7527..7537

Exogenous IL-33 promotes tumor immunity via macroscopic regulation of ILC2s

Interleukin-35 expression promotes hepatocellular carcinogenesis by inducing γδ T-cell exhaustion

The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.

IL-23 Promotes the Development of Hepatocellular Carcinoma Through the Induction of IL-17-producing ILC3 (TUM10P.1044)

The role of IL-36 and 37 in hepatocellular carcinoma

IL-6 Promotes Hepatocellular Carcinoma Invasion by Releasing Exosomal miR-133a-3p

SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape

The Role of Interleukin-33 in Head and Neck Squamous Cell Carcinoma Is Determined by Its Cellular Sources in the Tumor Microenvironment

Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma

IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma